Spirogen was founded in 2000 as a spin-out from several institutions including University College London and with partial funding by what is now Cancer Research Horizons.

Spirogen, a biotech company focused on antibody-drug conjugage technology for use in oncology, was acquired by AstraZeneca’s MedImmune in 2013 for an initial consideration of $200M and deferred consideration of up to $240M based on reaching predetermined development milestones. 

Case study: Coming together for Zynlonta: how scientific expertise, funding and entrepreneurship came together for the development of an antibody-drug conjugate targeting lymphoma